AstraZeneca (LON:AZN)has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel  ...

AstraZeneca plc with EPIC/TICKER (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Kepler Cheuvreux. AstraZeneca plc are listed ...

AstraZeneca (LON:AZN) announced its year-to-date and Q3 2019 results. Year-to-date Product Sales growth of 13% (17% at CER1) to $17,315m included third-quarter Product Sales of $6,132m (+16%, +18% at CER). ...

AstraZeneca (LON:AZN) announced that the US Food and Drug Administration has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes  and established cardiovascular disease or ...

AstraZeneca (LON:AZN) and Daiichi Sankyo Company Limited announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) ...

Shares in AstraZeneca with EPIC code: LON:AZN has decreased -1.32% or -92 points throughout today’s trading session so far. Traders have not remained optimistic throughout the trading session. The high ...

AstraZeneca plc using EPIC/TICKER code (LON:AZN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ today by analysts at Jefferies International. AstraZeneca plc are ...

Fasenra is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing AstraZeneca plc (LON: AZN) has today ...

AstraZeneca (LON: AZN) has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arzneimittel GmbH (Cheplapharm). The ...

Shares in AstraZeneca EPIC code: LON:AZN has stepped up 1.34% or 96 points during the course of today’s session so far. Investors have remained positive throughout the session. Range high ...